Skip to main content

School counselor who stopped school shooter arrested on prostitution-related charges

Click here for updates on this story

    BALTIMORE (WJZ) — A Baltimore County school counselor, credited for tackling a school shooter at Perry Hall back in 2012, has been arrested on a misdemeanor count of attempting to patronize a prostitute.

Jesse Wasmer, a man once hailed as a hero, was allegedly caught trying to pay for sexual acts at Crystal Therapy, a spa located in Wilmington, Delaware.

“When you are a teacher with the school system, and this happens, it hurts more,” Kevin Bethea, a Baltimore County resident, said.

New Castle County Police in Delaware say Wasmer and another man were arrested during the incident.

“It’s unfortunate when these things happen,” Bethea added.

Bethea’s daughter went to Perry Hall High School and still has ties there.

Back in 2012, Wasmer tackled a school shooter and held him down until police arrived and placed the man under arrest. Many say his actions saved lives.

Bethea says he remembers the day and was amazed at Wasmer’s actions, but now feels there’s a blemish on his record.

“It was a good thing what he did, but now finding this out, it just lessens it and turns it into a different story,” Bethea explained.

Police say they were at Crystal Spa on July 15 for a drug and human trafficking investigation.

According to officers, three women were found as victims who were forced to work 12-hour shifts, seven days a week, without being paid properly.

Officers seized more than $15,000 and bulk quantities of condoms from the spa.

Both the owner and operator were arrested by police and charged with multiple felony counts.

“A lot of times you might have individuals that start out doing the right things and acts of heroism, but then they get caught up in situations like this,” Bethea said.

Wasmer had been working at Bear Creek Elementary, Grange Elementary, Sandy Plains Elementary, and Patapsco High School, according to a letter, obtained by WJZ, that the principal of Bear Creek sent to families.

Wasmer is now on administrative leave and is barred from the school, per the notice. Support staff is available to students and their families if they have questions or want to talk about the situation.

Meanwhile, on social media, many people remain in Wasmer’s corner, saying it doesn’t matter what he did; they still consider him a hero.

Please note: This story was provided to CNN Wire by an affiliate and does not contain original CNN reporting. This content carries a strict local market embargo. If you share the same market as the contributor of this article, you may not use it on any platform.

Personalized mRNA cancer vaccine shows promise in extending lifespan in melanoma trial

Stock photo of a doctor examining a patient's skin. (Lordhenrivoton/STOCK PHOTO/Getty Images)(NEW YORK) -- Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination regimen that demonstrated success in potentially extending melanoma patients' lifespans.In Phase 3 trials, the regimen significantly reduced the risk of cancer returning or spreading. The trial was conducted among patients whose high-risk melanoma had been surgically removed.The combination treatment regimen pairs the personalized vaccine with Merck's Keytruda, which had previously been used to treat the cancer alone.The treatment showed a 49% reduction of melanoma return after patients underwent surgery and a 59% reduction of metastasization of the cancer to distant organs.Key questions surrounding regulatory review of the vaccine remain.The Food and Drug Administration has not yet approved the vaccine. The agency will review the full data once it has been collected and submitted.While the FDA has already approved other cancer vaccines, this new treatment represents a step forward in the field as it uses mRNA technology and personalized treatment for each patient.Merck and Moderna plan to present data at an upcoming international medical meeting where they hope to engage regulators on filing submissions for approval of the regimen, the companies said in a joint press release.Dr. Ahmad Tarhini, an oncologist at the H. Lee Moffitt Cancer Center & Research Institute, told ABC News that he expects the treatment to be approved based on very positive trial results and made available to patients likely by early 2027.The vaccine uses genetic information from patients' individual tumors to identify and attack the cancer."It's what we call individualized neoantigen therapy, where we take the cancer itself, we do genetic sequencing and try to define a unique mutational fingerprint of the cancer itself," Tarhini said.Melanoma is the deadliest form of skin cancer, with about 112,000 new cases expected in 2026, according to the American Cancer Society.The treatment is considered relatively safe, according to the companies. The most common side effects include fatigue, sore arm and chills.Treatments utilizing mRNA technologies are being used in trials for other forms of cancer, including that of the bladder, kidney, lungs, stomach and pancreas, according to Tarhini."I think it will certainly improve the outcome of our patients," Tarhini said. "We are, you know, excited about this development. My expectation is this will eventually change the standard care of our patients."Copyright © 2026, ABC Audio. All rights reserved.
Read Next Story